Top Markets
#1 Electroneum Electroneum +18.52%
#2 Status Status +15.80%
#3 Ski Mask Dog Ski Mask Dog +9.20%
#4 Thena Thena +9.19%
#5 Infinity Ground Infinity Ground +8.96%
#6 Strategic Oil Supply Strategic Oil Supply +6.85%
#7 TG.Casino TG.Casino +6.38%
#8 City Boy City Boy +4.69%
#9 Hex Trust USD Hex Trust USD +4.55%
#10 Bitway Bitway +4.45%
Coin of the day
Electroneum Electroneum
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rang în acțiuni #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preț acțiune
$451.59
Capitalizare de piață
$114.70B
Schimbare (1 zi)
-2.36%
Schimbare (1 an)
-11.89%
Țară
US
Tranzacționează Vertex Pharmaceuticals Incorporated (VRTX)

Categorie

Healthcare
Venituri pentru Vertex Pharmaceuticals Incorporated (VRTX)
Venituri în Dec 2025 TTM: $12.04B
Conform celor mai recente rapoarte financiare ale Vertex Pharmaceuticals Incorporated, venitul actual al companiei (TTM) este $12.04B. În anul 2024, compania a avut un venit de $11.02B o creștere față de venitul din anul 2023, care a fost de $9.87B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Vertex Pharmaceuticals Incorporated din 2000 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $12.04B 0.31%
2025 $12.00B 8.90%
2024 $11.02B 11.66%
2023 $9.87B 10.51%
2022 $8.93B 17.91%
2021 $7.57B 22.06%
2020 $6.21B 49.07%
2019 $4.16B 36.59%
2018 $3.05B 22.46%
2017 $2.49B 46.20%
2016 $1.70B 64.89%
2015 $1.03B 77.86%
2014 $580.42M -52.11%
2013 $1.21B -20.63%
2012 $1.53B 8.25%
2011 $1.41B 883.91%
2010 $143.37M 40.49%
2009 $102.05M -41.85%
2008 $175.50M -11.81%
2007 $199.01M -8.02%
2006 $216.36M 34.47%
2005 $160.89M 56.63%
2004 $102.72M 48.56%
2003 $69.14M -57.08%
2002 $161.09M -3.82%
2001 $167.49M 114.38%
2000 $78.13M 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 302.35%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 19.14%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -24.56%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 30.38%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -54.39%
NL